2023-11-10T14:46:59-06:00 2022-12-31 221478099 COHNREZNICK LLP 7501 WISCONSIN AVENUE SUITE 400E BETHESDA MD 20814 990 2022-01-01 136180380 AMERICAN SOCIETY OF CLINICAL ONCOLOGY INC AMER 5714831300 2318 MILL ROAD 800 ALEXANDRIA VA 22314 LINDA JENSEN EVP & CFO 5714831300 2023-11-09 1 LINDA JENSEN 999009999 1 LORI ROTHE YOKOBOSKY CPA P01273422 3016529100 2023-11-06 2 AAL1 IAL1 2022 2023-04-26 12:10:37Z ASCO CLIFFORD HUDIS MD CEO 2318 MILL ROAD 800 ALEXANDRIA VA 22314 168708422 0 X WWW.ASCO.ORG X 1965 NY SEE SCHEDULE O:ASCO IS A PROFESSIONAL ONCOLOGY SOCIETY COMMITTED TO CONQUERING CANCER THROUGH RESEARCH, EDUCATION, AND PROMOTION OF THE HIGHEST QUALITY, EQUITABLE PATIENT CARE. 18 18 523 4749 15104014 8114539 7826511 9250760 95200297 123943513 -6626473 2024051 11188293 10921536 107588628 146139860 4188723 4042358 0 0 59715405 64467166 0 0 0 55874509 75760362 119778637 144269886 -12190009 1869974 283820689 251452025 114592790 107117119 169227899 144334906 X SEE SCHEDULE O: 0 0 52117766 88066942 SEE SCHEDULE O:SCIENTIFIC & MEDICAL EDUCATION:IN 2022, ASCO'S ANNUAL MEETING (THE ASCO ANNUAL MEETING IS THE WORLD'S PREMIER SCIENTIFIC AND EDUCATIONAL CLINICAL ONCOLOGY MEETING), THROUGH OVER 200 SESSIONS, REACHED AN AUDIENCE OF 34,250 PROFESSIONALS, INCLUDING OVER 14,000 PROFESSIONALS FROM 136 NON-US COUNTRIES, BOTH IN-PERSON AND ONLINE. THROUGH ASCO'S ADDITIONAL MEETINGS, THE ASCO GASTROINTESTINAL CANCERS SYMPOSIUM, THE ASCO GENITOURINARY CANCERS SYMPOSIUM, THE ASCO QUALITY CARE SYMPOSIUM, AND THE BEST OF ASCO ANNUAL MEETING, A FURTHER 9,250 PROFESSIONALS, OVER 4,000 OF WHOM WERE FROM OUTSIDE THE UNITED STATES, BENEFITED FROM THE EDUCATION, SCIENCE, AND NETWORKING THAT ASCO PROVIDED. 29294472 15043881 SEE SCHEDULE O:QUALITY OF CARE INITIATIVES - CANCERLINQ, QUALITY MEASURES, GUIDELINES AND QOPI:CANCERLINQ IS A HEALTH TECHNOLOGY PLATFORM, DEVELOPED AND IMPLEMENTED BY ASCO, THAT AGGREGATES ELECTRONIC HEALTH RECORD DATA TO IMPROVE THE QUALITY OF CARE AND HEALTH OUTCOMES FOR ALL PATIENTS WITH CANCER AND TO ADVANCE EVIDENCE-BASED RESEARCH. IN 2022, CANCERLINQ'S PRACTICE FACING QUALITY MANAGEMENT AND REPORTING PLATFORM SMARTLINQ SERVED 67 ONCOLOGY PRACTICES AND CANCER CENTERS ACROSS THE US, INCLUDING 3 THAT JOINED THE NETWORK IN 2022. SMARTLINQ WAS REFRESHED IN 2022 WITH A NEW HOMEPAGE AND FEATURES. INSIDE SMARTLINQ, A SUITE OF DASHBOARDS, REPORTS, AND QUALITY MEASURE TOOLS ENABLE PRACTICE TEAMS TO TRACK THE QUALITY OF CANCER CARE AUTOMATICALLY AND PROACTIVELY, AND THE 11 UNIQUE REPORTING DASHBOARDS THAT ARE PART OF THE CANCERLINQ INSIGHTS TOOL ASSIST ONCOLOGISTS WITH CLINICAL DECISION-MAKING AND PRACTICE INSIGHTS. ADDITIONALLY, THROUGH CANCERLINQ DISCOVERY, 10 TUMOR SITE-SPECIFIC REAL-WORLD DATASETS HAVE BEEN MADE AVAILABLE TO THE RESEARCH COMMUNITY, AND IN 2022 THESE WERE UTILIZED BY A TOTAL OF 30 CANCER RESEARCHERS ACROSS 10 ACADEMIC INSTITUTIONS. IN 2022, THERE WERE A TOTAL OF 6 MANUSCRIPTS PUBLISHED IN PEER-REVIEWED JOURNALS AND 18 ABSTRACTS ACCEPTED TO SCIENTIFIC MEETINGS THAT USED DATA FROM CANCERLINQ."QUALITY ONCOLOGY PRACTICE INITIATIVE (QOPI). A QUALITY SELF ASSESSMENT AND IMPROVEMENT PROGRAM FOR OUTPATIENT MEDICAL ONCOLOGY AND HEMATOLOGY-ONCOLOGY PRACTICES: QOPI PROVIDES A WEB-BASED DATA COLLECTION TOOL THAT ALLOWS PRACTICES TO 1) REPORT ON VARIOUS CANCER CARE QUALITY MEASURES, 2) RECEIVE ANALYZED DATA ON PRACTICE PERFORMANCE, AND 3) COMPARE PERFORMANCE AGAINST THEIR PEERS FOR DATA-DRIVEN IMPROVEMENT ACTIVITIES. PRACTICES PARTICIPATE ANNUALLY AND OVER 300 PRATICES PARTICAPTED IN 2022.QUALITY TRAINING PROGRAM. ASCO'S QUALITY TRAINING PROGRAM IS DESIGNED TO EDUCATE AND TRAIN HEMATOLGY-ONOCOLOGY PRACTICE TEAMS, THE TECHNIQUES OF CLINICAL CARE AND OPERATIONAL PERFORMANCE QUALITY IMPROVEMENT. RECENT PARTICPANTS HAVE INCLUDED, BY INTENTIONAL RECRUITMENT, PRACTICES SERVING URBAN AND RURAL UNDERSERVED POPULATIONS ADRESSING HEALTH DISPARITY. 287 ONCOLOGY PROFESSIONALS RECEIVED TRAINING IN 2022." 11612155 2195605 SEE SCHEDULE O:RESEARCH INITIATIVES - TAPUR/CENTRA:ASCO'S CENTER FOR RESEARCH AND ANALYTICS (CENTRA) LEADS ASCO'S EFFORTS IN RESEARCH AND RELATED TO CLINICAL CANCER RESEARCH. MAJOR PROGRAMS AND PROJECTS INCLUDE: (1) THE TARGETED AGENT AND PROFILING UTILIZATION REGISTRY (TAPUR) WHICH IS A PRECISION MEDICINE BASKET TRIAL INVESTIGATING THE EFFICACY OF MORE THAN 15 DIFFERENT ANTI-CANCER TARGETED AGENTS IN PATIENTS WITH ADVANCED CANCERS AND HAS ENROLLED MORE THAN 2600 PATIENTS SINCE IT OPENED IN 2016. IN 2022, THE TAPUR TEAM SUBMITTED 7 ABSTRACTS AND 4 MANUSCRIPTS; (2) ASCO'S COVID-19 REGISTRY WHICH INCLUDES A DATABASE OF OVER 6000 PATIENTS WITH CANCER AND COVID-19 FROM 2020 TO 2022 AND RESEARCH ON THE DATABASE BY CENTRA STAFF AND MADE AVAILABLE TO EXTERNAL RESEARCHERS WITH A TOTAL OF 5 SUBMITTED MANUSCRIPTS AND 6 ABSTRACTS; (3) ASCO'S MEMBER RESEARCH SURVEY POOL, WHICH FACILITATES RESEARCH OF CANCER CARE PROVIDERS BY DISSEMINATING SURVEYS FROM MERITORIOUS SURVEY RESEARCH PROJECTS TO ASCO MEMBERS WHO HAVE AGREED TO BE A PART OF THE SURVEY POOL; (4) THE STATE OF CANCER CARE IN AMERICA PROGRAM, WHICH HAS A RESEARCH AGENDA TO ASSESS AND REPORT ON THE STATE OF AND CHANGES IN CANCER CARE IN THE US, AND (5) ASCO'S SITE SELF-ASSESSMENT TOOL AND IMPLICIT BIAS TRAINING, BOTH OF WHICH WERE DEVELOPED IN COLLABORATION WITH THE ASSOCIATION OF COMMUNITY CANCER CENTERS WITH THE OBJECTIVE OF INCREASING REPRESENTATIVE OF MINORITY ENROLLMENT ON CANCER CLINICAL TRIALS. CENTRA ALSO SUPPORTS WORKSHOPS, MEETINGS, AND RESEARCH PROJECTS WITH OTHER STAKEHOLDERS IN CANCER RESEARCH, INCLUDING THE NCI, THE FDA'S ONCOLOGY CENTER FOR EXCELLENCE, AND OTHER NON-PROFIT GROUPS, SUCH AS THE FRIENDS OF CANCER RESEARCH. 28157026 4042358 18637085 EXAMPLES OF OTHER PROGRAMS - PUBLICATIONS, PUBLIC INFORMATION AND POLICY:SCIENTIFIC PUBLICATIONS: ASCO PRODUCES A NUMBER OF PROFESSIONAL PUBLICATIONS AND GENERAL PUBLICATIONS FOCUSED ON CLINICAL ONCOLOGY. ASCO PUBLISHES HIGH-QUALITY, PEER-REVIEWED SCIENTIFIC PAPERS IN ITS JOURNALS: - JOURNAL OF CLINICAL ONCOLOGY (JCO)- JCO ONCOLOGY PRACTICE (JCO OP)- JCO GLOBAL ONCOLOGY (JCO GO)- JCO CLINICAL CANCER INFORMATICS (JCO CCI)- JCO PRECISION ONCOLOGY (JCO PO)- ASCO DAILY NEWSASCO ALSO PROVIDES CONTENT AND DISTRIBUTION LISTS FOR TRADE PUBLICATIONS. WHILE NOT OWNED OR PUBLISHED BY ASCO, THE PUBLICATIONS COVER NEWS AND INFORMATION OF INTEREST TO THE PROFESSIONAL ONCOLOGY COMMUNITY.PATIENT & PUBLIC INFORMATION:ASCO PROVIDES TIMELY, CREDIBLE, AND COMPREHENSIVE CANCER INFORMATION FREE OF CHARGE THROUGH ITS AWARD-WINNING WEBSITE, CANCER.NET (WWW.CANCER.NET), MOBILE APPLICATION, AND PRINT MATERIALS. CANCER.NET, WHICH CELEBRATED ITS 20TH ANNIVERSARY IN 2022, COVERS 120+ TYPES OF CANCER AND CANCER-RELATED SYNDROMES AND EVERY ASPECT OF CANCER CARE AND SURVIVORSHIP, AS WELL AS OFFERING TIMELY AND TRUSTED CANCER INFORMATION FOR PEOPLE AFFECTED BY GLOBAL EVENTS SUCH AS COVID-19 AND THE CONFLICT IN UKRAINE. ADDITIONAL INITIATIVES INCLUDED A SOCIAL MEDIA OUTREACH CAMPAIGN FOCUSED ON MENTAL HEALTH RESOURCES FOR PATIENTS AND CAREGIVERS THAT RECEIVED OVER 3 MILLION IMPRESSIONS, A SERIES OF ARTICLES DEBUNKING COMMON CANCER-RELATED MYTHS THAT RECEIVED OVER 400,000 PAGE VIEWS, AND A CONTENT-SHARING COLLABORATION WITH THE AMERICAN CANCER SOCIETY THAT RESULTED IN OVER 38,000 PAGE VIEWS OF THE SHARED CONTENT ACROSS BOTH SITES IN THE FIRST YEAR. OVER THE COURSE OF 2022, MORE THAN 57 MILLION PAGES ON CANCER.NET WERE VIEWED BY 29 MILLION PEOPLE WORLDWIDE. CONTENT IS DEVELOPED AND REVIEWED BY AN EDITORIAL BOARD COMPOSED OF 200+ MEDICAL, SURGICAL, RADIATION, AND PEDIATRIC ONCOLOGISTS; MULTIDISCIPLINARY MEMBERS OF THE ONCOLOGY TEAM SUCH AS NURSES, PHYSICIAN ASSISTANTS, AND SOCIAL WORKERS; AS WELL AS PATIENT ADVOCATES. INFORMATION IS AVAILABLE IN ENGLISH AND SPANISH, WITH SELECT RESOURCES AVAILABLE IN 9 ADDITIONAL LANGUAGES.POLICY:ASCO WORKS TO SHAPE A WIDE RANGE OF POLICY ISSUES THAT IMPACT THE CANCER CARE DELIVERY SYSTEM AND PEOPLE WITH CANCER. THE SOCIETY'S GOAL IS TO ENSURE THAT ALL PATIENTS HAVE ACCESS TO HIGH-QUALITY, AFFORDABLE CANCER CARE AND ONCOLOGY PRACTICES HAVE THE RESOURCES NEEDED TO PROVIDE THAT CARE. KEY AREAS OF FOCUS INCLUDE QUALITY AND ACCESS TO CARE, MEDICAL INSURANCE COVERAGE ISSUES, COST, DISPARITIES, PREVENTION, SURVIVORSHIP, REIMBURSEMENT, AND SUPPORT FOR CLINICAL CANCER RESEARCH. IN 2022, ASCO DREW PUBLIC ATTENTION TO THE HARMS OF PRIOR AUTHORIZATION WITH A POLICY STATEMENT DESCRIBING THE ADVERSE IMPACT OF PRIOR AUTHORIZATION ON PATIENTS AND OFFERING SEVERAL RECOMMENDATIONS FOR ADDRESSING CONCERNS. 28157026 4042358 18637085 121181419 1 1 0 1 0 0 0 0 0 0 1 0 0 0 1 1 0 1 0 1 1 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 0 1 451 0 1 523 1 1 1 0 0 0 0 0 0 0 0 0 0 0 X 18 18 0 0 0 0 1 1 1 1 1 0 0 1 1 1 1 1 1 1 1 0 CA NY VA X LINDA JENSEN EVP & CFO 5714831300 2318 MILL ROAD SUITE 800 ALEXANDRIA VA 22314 CLIFFORD A HUDIS MD CEO 30.00 7.50 X 930020 0 22875 DINA MICHELS ESQ SECRETARY, EVP & COO 37.50 X 618646 0 39119 JULIE R GRALOW MD EVP & CMO 37.50 X 583947 0 39119 SEAN KHOZIN MD EVP & CLQ CEO (PARTIAL YEAR) 37.50 X 507012 0 29592 NANCY DALY MS MPH EVP & CONQUER CANCER CEO 1.00 36.50 X 477749 0 39092 CHRISTOPHER MERLAN EVP & CHIEF DIGITAL OFFICER 37.50 X 445619 0 44127 LINDA JENSEN EVP & CFO 30.00 7.50 X 431666 0 39119 JAMIE VON ROENN MD MED VP, EDU., SCIENCE & PROF. 37.50 X 434759 0 31264 STEPHEN GRUBBS MD VP, CARE DELIVERY 37.50 X 421274 0 38575 ROBERT MILLER MD CLQ CHIEF MEDICAL SCIENCE OFFICER 37.50 X 371680 0 39092 CARMEN JACKSON INTERIM CEO CLQ 37.50 X 359782 0 45254 PAULA KING CHIEF HUMAN RESOURCES OFFICER 37.50 X 335721 0 44127 DEBORAH KAMIN PHD VP, POLICY/ADVOCACY 30.00 7.50 X 330564 0 39092 ANGELA COCHRAN VP, PUBLISHING 37.50 X 307569 0 36737 AMANDA DAVIS-AITKEN VICE PRESIDENT, MEETING SV 37.50 X 309515 0 30642 BARTON LAWYER VICE PRESIDENT - IT 37.50 X 283914 0 43379 EVERETT E VOKES MD PRESIDENT/CHAIR 1.00 1.00 X X 0 0 0 ERIC P WINER MD PRESIDENT-ELECT/PRESIDENT 1.00 1.00 X X 0 0 0 LYNN M SCHUCHTER MD PRESIDENT-ELECT (PARTIAL YEAR) 1.00 1.00 X X 0 0 0 LORI J PIERCE MD CHAIR/PAST PRESIDENT 1.00 1.00 X X 0 0 0 LAURIE E GASPAR MD MBA TREASURER (PARTIAL YEAR) 1.00 1.00 X X 0 0 0 ELIZABETH A MITTENDORF MD PHD MHC TREASURER 1.00 1.00 X X 0 0 0 ELIZABETH R PLIMACK MD MS TREASURER-ELECT (PARTIAL YEAR) 1.00 1.00 X X 0 0 0 FREDERICK CHITE ASIRWA MD MBCHB BOARD MEMBER (PARTIAL YEAR) 1.00 X 0 0 0 ETHAN M BASCH MD MSC BOARD MEMBER 1.00 1.00 X 0 0 0 A WILLIAM BLACKSTOCK MD BOARD MEMBER (PARTIAL YEAR) 1.00 1.00 X 0 0 0 LISA A CAREY MD BOARD MEMBER 1.00 X 0 0 0 MARIANA CHAVEZ MACGREGOR MD MSC BOARD MEMBER 1.00 X 0 0 0 LEE M ELLIS MD BOARD MEMBER (PARTIAL YEAR) 1.00 1.00 X 0 0 0 TARA O HENDERSON MD MPH BOARD MEMBER 1.00 X 0 0 0 CAROLYN B HENDRICKS MD BOARD MEMBER (PARTIAL YEAR) 1.00 X 0 0 0 TONY S K MOK MD BOARD MEMBER (PARTIAL YEAR) 1.00 1.00 X 0 0 0 TAOFEEK K OWONIKOKO MD PHD BOARD MEMBER 1.00 X 0 0 0 ANN H PARTRIDGE MD MPH BOARD MEMBER (PARTIAL YEAR) 1.00 X 0 0 0 ENRIQUE SOTO PEREZ DE CELIS MD MSC BOARD MEMBER 1.00 X 0 0 0 GLADYS I RODRIGUEZ MD BOARD MEMBER 1.00 X 0 0 0 MICHAEL A THOMPSON MD PHD BOARD MEMBER 1.00 X 0 0 0 TRACEY F WEISBERG MD BOARD MEMBER (PARTIAL YEAR) 1.00 1.00 X 0 0 0 KAREN M WINKFIELD MD PHD BOARD MEMBER (PARTIAL YEAR) 1.00 X 0 0 0 7149437 0 601205 231 0 1 0 FREEMAN PO BOX 734596 DALLAS TX 753734596 EVENT MANAGEMENT 8832653 SPARGO INC 11208 WAPLES MILL ROAD 112 FAIRFAX VA 22030 EVENT MANAGEMENT 4291808 AMAZON WEB SERVICES PO BOX 84023 SEATTLE WA 981248423 IT SERVICES 3069658 KUSHNER & ASSOCIATES 4500 PARK GRANADA STE 202 CALABASAS CA 91302 TRANSPORTATION SERVICES 2160117 CONCERTO HEALTHAI SOLUTIONS LLC 501 BOLYSTON ST BOSTON MA 02116 DATA TECHNOLOGY 1889768 89 9233468 17292 9250760 EDUCATIONAL MTGS & FEE 900099 88516797 80240140 8276657 SCIENTIFIC PUBLICATION 513120 17778821 10951464 6827357 QUALITY OF CARE 900099 13926990 13926990 RESEARCH 900099 2194405 2194405 OTHER 900099 1526500 1526500 123943513 4158517 4158517 9231347 9231347 1690189 0 1690189 1690189 1690189 20434096 22548899 19663 -2114803 -19663 -2134466 -2134466 146139860 108839499 15104014 12945587 X 4042358 4042358 5725484 3835832 1889652 45992210 37021016 8971194 3299448 2210490 1088958 5710477 3825778 1884699 3739547 2505338 1234209 843705 843705 149367 149367 76549 76549 19797310 18279375 1517935 1069735 1044639 25096 5286726 4128690 1158036 10278288 10044265 234023 3504493 2320019 1184474 4140167 3349508 790659 19071459 19045229 26230 1150463 634591 515872 3672255 2026228 1646027 919909 691273 228636 UBI TAX- FEDERAL AND ST 2624016 2523290 100726 CLINICAL SITE PAYMENTS 2300750 2300750 OTHER 557162 509045 48117 BAD DEBT 318008 318008 144269886 121181419 23088467 0 103 25343458 15476157 13783464 11423325 4696784 5397152 5887690 85349720 38091111 46930865 47258609 181953164 166910803 5715699 4495441 283820689 251452025 11649507 9387248 46913692 46146231 49295410 46440487 6734181 5143153 114592790 107117119 X 168691045 143605840 536854 729066 169227899 144334906 283820689 251452025 1869974 -26762969 2 0 X 0 1 X 1 0 X 8575801 7525300 6446971 7826511 9250760 39625343 136574903 123116955 98737324 80888354 108839499 548157035 145150704 130642255 105184295 88714865 118090259 587782378 75000 75000 0 75000 75000 587707378 7763043 8610595 18248056 15214892 15080053 64916639 7763043 8610595 18248056 15214892 15080053 64916639 4855029 7776132 8302393 7677032 8115539 36726125 255345 251085 506430 158024121 147280067 131734744 111606789 141285851 689931572 0.85180 0.86670 0.09410 0.08440 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 0 0 144269886 144269886 1000000 250000 0 0 1000000 1000000 1000000 1000000 4000000 6000000 43604 43604 250000 250000 250000 250000 1000000 1500000 263 263 54284456 16948355 37336101 763557 759189 4368 14350262 9897158 4453104 15951445 10486409 5465036 47258609 DEFERRED COMPENSATION LIABILITY 2702809 OPERATING LEASE OBLIGATION 2440344 5143153 X PART X, LINE 2: THE ORGANIZATION ACCOUNTS FOR UNCERTAINTY IN INCOME TAXES IN ACCORDANCE WITH THE INCOME TAX TOPIC OF THE FINANCIAL ACCOUNTING STANDARDS BOARD ACCOUNTING STANDARDS CODIFICATION ("FASB ASC"). THE ORGANIZATION BELIEVES THAT IT HAS APPROPRIATE SUPPORT FOR ANY TAX POSITIONS TAKEN AND, AS SUCH, DOES NOT HAVE ANY UNCERTAIN TAX POSITIONS THAT ARE MATERIAL TO THE CONSOLIDATED FINANCIAL STATEMENTS. GENERALLY, THE ORGANIZATION IS NO LONGER SUBJECT TO INCOME TAX EXAMINATIONS BY THE U.S. FEDERAL, STATE OR LOCAL TAX AUTHORITIES FOR YEARS BEFORE 2019. 1 NORTH AMERICA - CANADA AND MEXICO, BUT NOT THE UNITED STATES 0 5 PROGRAM SERVICES QUALITY OF CARE 951750 EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, 0 0 PROGRAM SERVICES OUTREACH & EDUCATION 141872 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM 0 0 PROGRAM SERVICES OUTREACH & EDUCATION 119327 SOUTH ASIA - AFGHANISTAN, BANGLADESH, BHUTAN, INDIA, MALDIVES, NEPAL, 0 0 PROGRAM SERVICES OUTREACH & EDUCATION 51810 SOUTH AMERICA - ARGENTINA, BOLIVIA, BRAZIL, CHILE, COLUMBIA, ECUADOR, 0 0 PROGRAM SERVICES OUTREACH & EDUCATION 40010 SUB-SAHARAN AFRICA - ANGOLA, BENIN, BOTSWANA, BURKINA FASO, 0 0 PROGRAM SERVICES OUTREACH & EDUCATION 24700 RUSSIA AND NEIGHBORING STATES 0 0 PROGRAM SERVICES OUTREACH & EDUCATION 14742 MIDDLE EAST AND NORTH AFRICA 0 0 PROGRAM SERVICES OUTREACH & EDUCATION 10324 0 5 0 0 0 5 1354535 0 1354535 0 0 0 0 0 1 PART I, LINE 2: ASCO PROVIDED HONORARIA AND EXPENSE REIMBURSEMENTS TO MEETING SPEAKERS AND PRESENTERS. HONORARIA AND EXPENSE REIMBURSEMENTS WERE PAID DIRECTLY TO THE PRESENTERS. PART I, LINE 3: THE ACCRUAL METHOD WAS USED TO ACCOUNT FOR EXPENDITURES IN RELATION TO FOREIGN PROGRAM SERVICES. PART III ACCOUNTING METHOD: 1 NATIONAL ACADEMIES SCIENCES ENGINEERING MEDICINE 500 FIFTH STREET NW 8TH FLOOR WASHINGTON DC 20001 530196932 501(C)(3) 20000 0 CONTRIBUTION NATIONAL COALITION FOR CANCER SURVIVORSHIP 8455 COLESVILLE RD SUITE 930 SILVER SPRINGS MD 20910 850357897 501(C)(3) 10000 0 CONTRIBUTION HEALTH VOLUNTEERS OVERSEAS 1900 L STREET NW STE 310 WASHINGTON DC 20036 521485477 501(C)(3) 10000 0 CONTRIBUTION UNIVERSITY OF CHICAGO 5801 ELLIS AVE CHICAGO IL 60637 362177139 501(C)(3) 130000 0 CONTRIBUTION BOARD OF REGENTS OF THE UNIVERSITY OF THE UNIVERSITY OF MICHIGAN 3003 S STATE ST SUITE 8000 ANN ARBOR MI 48109 386006309 501(C)(3) 35000 0 CONTRIBUTION YALE UNIVERSITY PO BOX 208239 NEW HAVEN CT 06520 060646973 501(C)(3) 115833 0 CONTRIBUTION BRIGHAM & WOMEN'S HOSPITAL INC 75 FRANCIS ST BOSTON MA 02116 042312909 501(C)(3) 53000 0 CONTRIBUTION UNIVERSITY OF PENNSYLVANIA 3451 WALNUT ST RM 305 PHILADELPHIA PA 19104 231352685 501(C)(3) 46667 0 CONTRIBUTION SARAH CANON RESEARCH INSTITUTE OF HCA HEALTHCARE 3322 WEST END AVE SUITE 900 NASHVILLE TN 37203 201557751 N/A 25000 0 CONTRIBUTION BANNER MEDICAL GROUP 1 N CENTRAL AVE SUITE 160 PHOENIX AZ 85004 900532830 501(C)(3) 25000 0 CONTRIBUTION FOX CHASE CANCER CENTER 3509 N BROAD ST RM 936 PHILADELPHIA PA 19140 231352156 501(C)(3) 15000 0 CONTRIBUTION CONQUER CANCER FOUNDATION OF ASCO 2318 MILL RD SUITE 800 ALEXANDRIA VA 22314 311667995 501(C)(3) 3514500 0 CONTRIBUTION 10 1 PART I, LINE 2: ASCO PROVIDES ASSISTANCE TO ORGANIZATIONS THAT SERVE THE CANCER CARE COMMUNITY. THE MAJORITY OF THESE GRANTS ARE MADE TO OTHER 501(C)(3) ORGANIZATIONS. GRANTS MADE TO NON-501(C)(3) ORGANIZATIONS ARE MADE PURSUANT TO A WRITTEN AGREEMENT THAT REQUIRED THE GRANT FUNDS TO BE USED FOR SPECIFIC EDUCATIONAL AND CHARITABLE PROJECTS, THAT THE GRANTEE RETURN ANY PORTION OF THE GRANT FUNDS THAT WERE NOT USED FOR SUCH PROJECTS, AND THAT THE GRANTEE PROVIDE ANNUAL NARRATIVE AND FINANCIAL REPORTS TO ASCO REGARDING GRANTEE'S USE OF THE GRANT FUNDS. X X X X X 1 0 0 0 0 0 0 1 0 CLIFFORD A HUDIS MD CEO 928832 0 0 0 1188 0 22875 0 0 0 952895 0 0 0 DINA MICHELS ESQ SECRETARY, EVP & COO 607458 0 10000 0 1188 0 22875 0 16244 0 657765 0 0 0 JULIE R GRALOW MD EVP & CMO 572759 0 10000 0 1188 0 22875 0 16244 0 623066 0 0 0 SEAN KHOZIN MD EVP & CLQ CEO (PARTIAL YEAR) 496678 0 10000 0 334 0 22875 0 6717 0 536604 0 0 0 NANCY DALY MS MPH EVP & CONQUER CANCER CEO 466561 0 10000 0 1188 0 22875 0 16217 0 516841 0 0 0 CHRISTOPHER MERLAN EVP & CHIEF DIGITAL OFFICER 434845 0 10000 0 774 0 22875 0 21252 0 489746 0 0 0 LINDA JENSEN EVP & CFO 419380 0 10000 0 2286 0 22875 0 16244 0 470785 0 0 0 JAMIE VON ROENN MD MED VP, EDU., SCIENCE & PROF. 421051 0 10000 0 3708 0 22875 0 8389 0 466023 0 0 0 STEPHEN GRUBBS MD VP, CARE DELIVERY 408988 0 10000 0 2286 0 22875 0 15700 0 459849 0 0 0 ROBERT MILLER MD CLQ CHIEF MEDICAL SCIENCE OFFICER 370492 0 0 0 1188 0 22875 0 16217 0 410772 0 0 0 CARMEN JACKSON INTERIM CEO CLQ 350102 0 9500 0 180 0 22875 0 22379 0 405036 0 0 0 PAULA KING CHIEF HUMAN RESOURCES OFFICER 324533 0 10000 0 1188 0 22875 0 21252 0 379848 0 0 0 DEBORAH KAMIN PHD VP, POLICY/ADVOCACY 316856 0 10000 0 3708 0 22875 0 16217 0 369656 0 0 0 ANGELA COCHRAN VP, PUBLISHING 297299 0 10000 0 270 0 22500 0 14237 0 344306 0 0 0 AMANDA DAVIS-AITKEN VICE PRESIDENT, MEETING SV 299335 0 10000 0 180 0 22500 0 8142 0 340157 0 0 0 BARTON LAWYER VICE PRESIDENT - IT 273500 0 10000 0 414 0 21000 0 22379 0 327293 0 0 0 PART I, LINE 4A SEAN KHOZIN RECEIVED A SEVERANCE PAYMENT IN THE AMOUNT OF $94,231 IN 2022. PART I, LINE 7 THE ORGANIZATION HAS A DISCRETIONARY BONUS PLAN UNDER WHICH SELECTED EMPLOYEES, INCLUDING OFFICERS, KEY EMPLOYEES, AND OTHER EMPLOYEES ARE COMPENSATED BASED ON PERFORMANCE AND THE ACHIEVEMENT OF ORGANIZATIONAL GOALS. BONUSES FOR KEY EMPLOYEES AND HIGHEST COMPENSATED EMPLOYEES ARE APPROVED BY THE CHIEF EXECUTIVE OFFICER WITH REVIEW AND APPROVAL BY THE COMPENSATION COMMITTEE OF THE BOARD, WHERE APPROPRIATE. BONUSES FOR THE CHIEF EXECUTIVE OFFICER, IF ANY, ARE REVIEWED BY THE COMPENSATION COMMITTEE AS PART OF THE CHIEF EXECUTIVE OFFICER'S ANNUAL COMPENSATION REVIEW PROCESS, AND APPROVED BY THE BOARD OF DIRECTORS. IN ADDITION, THE ORGANIZATION AWARDS MODEST AMOUNTS TO EMPLOYEES ON ACHIEVING CERTAIN NUMBER OF YEARS OF EMPLOYMENT. FROM TIME TO TIME, THE ORGANIZATION MAY MAKE STANDARD PAYMENTS TO ITS EMPLOYEES IN GOOD STANDING WITH MINIMUM TIME OF EMPLOYMENT TO RECOGNIZE EFFORT AND COMMITMENT TO THE ORGANIZATION'S GOALS IN THAT YEAR. FORM 990, PART VI, SECTION A, LINE 1A AS OF DECEMBER 31, 2021, THE BOARD OF DIRECTORS OF ASCO INCLUDED 18 MEMBERS WITH THE RIGHT TO VOTE ON ALL MATTERS THAT COME BEFORE THE BOARD OF DIRECTORS. THE BOARD OF DIRECTORS ALSO INCLUDED TWO EX-OFFICIO DIRECTORS WITHOUT THE RIGHT TO VOTE, WHO WERE THE CHIEF EXECUTIVE OFFICER OF ASCO (CEO) AND THE CHAIR OF THE BOARD OF DIRECTORS OF ASCO'S RELATED 501(C)(3) ORGANIZATION, THE CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY.. DURING THE REPORTING YEAR, THE BOARD OF DIRECTORS DELEGATED AUTHORITY TO ACT ON ITS BEHALF TO THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS, CONSISTENT WITH ASCO'S BYLAWS. PURSUANT TO THE BYLAWS, THE VOTING MEMBERS OF THE EXECUTIVE COMMITTEE ARE THE PRESIDENT, THE PRESIDENT-ELECT, THE CHAIR, THE PAST PRESIDENT, THE TREASURER, THE TREASURER-ELECT, AND THOSE DIRECTORS SERVING THE FINAL YEAR OF THEIR PRESENT TERMS. THE CEO IS A NON-VOTING MEMBER OF THE EXECUTIVE COMMITTEE. ALL EXECUTIVE COMMITTEE MEMBERS ARE MEMBERS OF ASCO'S BOARD OF DIRECTORS. THE SCOPE OF THE EXECUTIVE COMMITTEE'S AUTHORITY IS ESTABLISHED BY ASCO'S BYLAWS, WHICH PROVIDE THAT, EXCEPT TO THE EXTENT SPECIFICALLY PROHIBITED BY RESOLUTION OF THE BOARD OF DIRECTORS OR OTHERWISE PROHIBITED BY LAW, THE EXECUTIVE COMMITTEE OF THE BOARD IS EMPOWERED TO MAKE AND IMPLEMENT MAJOR DECISIONS BETWEEN BOARD MEETINGS, AND IT MAY ACT ON ITEMS REQUIRING ACTION PRIOR TO THE NEXT ANNOUNCED MEETING OF THE BOARD OF DIRECTORS. ALL ACTIONS OF THE EXECUTIVE COMMITTEE ARE REPORTED TO THE BOARD OF DIRECTORS AT THE NEXT MEETING OF THE BOARD OF DIRECTORS IMMEDIATELY FOLLOWING THE ACTION TAKEN BY THE EXECUTIVE COMMITTEE, CONSISTENT WITH ASCO'S BYLAWS. FORM 990, PART VI, SECTION A, LINE 6 ALL ASCO MEMBERS MUST BE ONCOLOGY MEDICAL PROFESSIONALS, DEFINED AS INDIVIDUALS WHO MEET ANY OF THE FOLLOWING QUALIFICATIONS: (1) INDIVIDUALS WHOSE PROFESSIONAL CREDENTIALS AND ACTIVITIES INVOLVE CANCER PATIENT CARE AND/OR RESEARCH, EDUCATION, OR ADVOCACY IN THE BIOLOGY, DIAGNOSIS, PREVENTION OR TREATMENT OF HUMAN CANCER; (2) INDIVIDUALS WHO ARE RETIRED FROM PROFESSIONAL ACTIVITIES, BUT WHOSE PROFESSIONAL ACTIVITIES PRIOR TO RETIREMENT INCLUDED THOSE SET FORTH ABOVE; (3) INDIVIDUALS WHO ARE STUDENTS TRAINING TO BE PROFESSIONALS DESCRIBED ABOVE. VOTING MEMBERS ARE ONCOLOGY MEDICAL PROFESSIONALS WHO HAVE BEEN AWARDED AND HOLD THE DEGREE OF DOCTOR OF MEDICINE, DOCTOR OF OSTEOPATHY, DOCTOR OF PHILOSOPHY, DOCTOR OF PHARMACY, DOCTOR OF MEDICAL SCIENCE, DOCTOR OF NURSING SCIENCE, DOCTOR OF NURSING PRACTICE, OR EQUIVALENT DOCTORAL-LEVEL DEGREE AS DETERMINED FROM TIME TO TIME BY ASCO AND THE ASSOCIATION. ONLY VOTING MEMBERS ARE ELIGIBLE TO VOTE OR SERVE ON THE BOARD OF DIRECTORS, ON THE NOMINATING COMMITTEE, OR AS ELECTED OFFICERS. FORM 990, PART VI, SECTION A, LINE 7A VOTING MEMBERS OF ASCO ELECT ALL VOTING MEMBERS OF THE ASCO BOARD OF DIRECTORS. FORM 990, PART VI, SECTION A, LINE 7B ASCO'S CERTIFICATE OF INCORPORATION MAY ONLY BE AMENDED UPON THE VOTE OF THE MEMBERS ENTITLED TO VOTE, AND THE BYLAWS MAY ONLY BE AMENDED, AND DISSOLUTION OF THE CORPORATION MAY ONLY BE APPROVED WITH THE APPROVAL OF BOTH THE BOARD OF DIRECTORS AND VOTING MEMBERS OF ASCO. FORM 990, PART VI, SECTION B, LINE 11B AN ELECTRONIC COPY OF THE FINAL FORM WAS SENT, THROUGH A SECURE SITE, TO EACH MEMBER OF THE BOARD OF DIRECTORS, AND WAS REVIEWED BY THE EXECUTIVE VICE PRESIDENT & CHIEF FINANCIAL OFFICER; THE CHIEF EXECUTIVE OFFICER; AND THE EXECUTIVE VICE PRESIDENT & CHIEF OPERATING OFFICER & CHIEF LEGAL OFFICER PRIOR TO FILING. FORM 990, PART VI, SECTION B, LINE 12C ASCO MAINTAINS A NUMBER OF WRITTEN CONFLICTS OF INTEREST POLICIES AND STANDARDS REGARDING THE DISCLOSURE AND MANAGEMENT OF CONFLICTS OF INTEREST. THESE POLICIES AND STANDARDS COVER ALL ASCO MEMBERS AND EMPLOYEES, DIRECTORS, OFFICERS, COMMITTEE MEMBERS, AND CERTAIN FAMILY MEMBERS (E.G. SPOUSE, DEPENDENT CHILDREN). COVERED INDIVIDUALS ARE ASKED TO DISCLOSE FINANCIAL INTERESTS IN OR OTHER RELATIONSHIPS WITH ENTITIES THAT HAVE RELEVANT COMMERCIAL INTERESTS, INCLUDING EMPLOYMENT OR LEADERSHIP POSITIONS, CONSULTANT OR ADVISORY ROLES, STOCK OWNERSHIP, HONORARIA, RESEARCH FUNDING, AND SERVICE AS AN EXPERT WITNESS. OFFICERS, DIRECTORS AND KEY EMPLOYEES ARE ALSO REQUIRED TO DISCLOSE SERVICE AS AN OFFICER, DIRECTOR, OR TRUSTEE OF ANY OTHER PROFESSIONAL OR ADVOCACY ORGANIZATION RELATING TO SCIENCE OR HEALTH CARE. COMPLETION OF A DISCLOSURE FORM IS REQUIRED AT THE INITIATION OF SERVICE AND UPDATED ANNUALLY THEREAFTER AND WHEN ANY MATERIAL CHANGES OCCUR. ASCO'S CONFLICT OF INTEREST POLICIES ARE INTENDED TO HELP GUIDE THE MANAGEMENT OF ACTUAL, POTENTIAL, AND PERCEIVED CONFLICTS OF INTEREST THROUGH DISCLOSURE OF FINANCIAL INTERESTS OR OTHER RELATIONSHIPS. WHERE THE NATURE AND EXTENT OF A FINANCIAL RELATIONSHIP SUGGEST DISCLOSURE IS NOT ADEQUATE TO MANAGE A REAL OR POTENTIAL CONFLICT, COVERED INDIVIDUALS ARE REQUIRED TO RECUSE THEMSELVES FROM DECISION-MAKING. RECUSAL MAY BE SELF-SELECTED, OR MAY BE REQUESTED BY THE COMMITTEE CHAIR, OFFICER, OR EXECUTIVE-LEVEL STAFF MEMBERS. IN ADDITION, IF ASCO WERE TO CONTEMPLATE ENTERING INTO A TRANSACTION OR ARRANGEMENT THAT MIGHT BENEFIT THE PRIVATE INTEREST OF ANY INTERESTED PERSON (I.E. AN ASCO DIRECTOR, PRINCIPAL OFFICER, OR MEMBER OF AN ASCO COMMITTEE WITH BOARD DELEGATED POWERS WHO HAS A DIRECT OR INDIRECT FINANCIAL INTEREST IN THE TRANSACTION), IT MUST FOLLOW A SPECIFIC PROCEDURE TO MANAGE THE CONFLICT, INCLUDING CONSIDERING ALTERNATIVE TRANSACTIONS THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. FORM 990, PART VI, SECTION B, LINE 15 COMPENSATION OF CHIEF EXECUTIVE OFFICER (CEO): THE DUTIES OF THE CEO OF ASCO INCLUDE SERVING AS: THE CEO OF ASCO, THE EXECUTIVE VICE CHAIR OF ASCO'S NON-PROFIT, 501(C)(3) TAX- EXEMPT RELATED ORGANIZATION, CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (CC); THE CEO OF ASCO'S NON-PROFIT, 501(C)(6) TAX-EXEMPT RELATED ORGANIZATION, ASCO ASSOCIATION (D/B/A ASSOCIATION FOR CLINICAL ONCOLOGY)(ASSOCIATION), THE PRESIDENT OF QOPI CERTIFICATION PROGRAM, LLC; THE PRESIDENT OF ASCO LEASING LLC, AND THE CHAIR OF THE BOARD OF GOVERNORS OF CANCERLINQ LLC. ALL ORGANIZATIONS LISTED ARE RELATED ORGANIZATIONS OF ASCO. THE WRITTEN EMPLOYMENT CONTRACT BETWEEN THE CEO AND ASCO ADDRESSES COMPENSATION OF THE CEO. THE COMPENSATION OF THE CEO WAS DETERMINED BY THE ASCO BOARD OF DIRECTORS, FOLLOWING THE REVIEW AND RECOMMENDATION OF THE BOARD COMPENSATION COMMITTEE. THE COMPENSATION COMMITTEE CONSULTED WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA (INCLUDING DATA ON COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS) AND PROVIDED ITS OPINION THAT THE COMPENSATION FOR THE CEO WAS REASONABLE. THE REVIEW, RECOMMENDATION, AND DETERMINATION OF THE CEO'S COMPENSATION BASED ON THE ABOVE-DESCRIBED PROCESS WAS MOST RECENTLY UNDERTAKEN IN 2022. THE COMPENSATION OF THE FOLLOWING POSITIONS WAS CONSIDERED AND APPROVED BY THE ASCO BOARD COMPENSATION COMMITTEE, AFTER RECEIVING THE RECOMMENDATION OF THE CEO AND AN INDEPENDENT COMPENSATION CONSULTANT. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA (INCLUDING DATA ON COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS) AND PROVIDED ITS OPINION THAT THE COMPENSATION FOR EACH OF THE POSITIONS WAS REASONABLE. - EXECUTIVE VICE PRESIDENT & CHIEF OPERATING OFFICER & CHIEF LEGAL OFFICER & ASCO SECRETARY (EVP & COO): THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE EVP & COO BASED ON THE ABOVE DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2021. THE EVP & COO'S COMPENSATION WAS ALSO REVIEWED AND APPROVED BY THE BOARD OF DIRECTORS, AS REQUIRED UNDER STATE LAW. - EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER (EVP & CFO): THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE EVP & CFO BASED ON THE ABOVE-DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2022. - EXECUTIVE VICE PRESIDENT & CHIEF MEDICAL OFFICER (EVP & CMO): THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE EVP & CMO BASED ON THE ABOVE-DESCRIBED PROCESS WAS MOST RECENTLY UNDERTAKEN IN 2022. - EXECUTIVE VICE PRESIDENT & CHIEF DIGITAL OFFICER (EVP & CDO): THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE EVP & CDO BASED ON THE ABOVE-DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2022. - EXECUTIVE VICE PRESIDENT OF ASCO & CHIEF EXECUTIVE OFFICER OF THE CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (EVP & CC CEO): THE EVP & CC CEO IS AN EMPLOYEE OF ASCO. THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE EVP & CC CEO BASED ON THE ABOVE-DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2022. - EXECUTIVE VICE PRESIDENT OF ASCO & CHIEF EXECUTIVE OFFICER OF CANCERLINQ LLC (EVP & CLQ CEO): THE EVP & CLQ CEO IS AN EMPLOYEE OF ASCO. THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE EVP & CC CEO BASED ON THE ABOVE-DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2022. FORM 990, PART VI, SECTION C, LINE 18 ASCO'S GOVERNING DOCUMENTS ARE AVAILABLE TO THE PUBLIC FROM ASCO UPON REQUEST. ASCO'S CERTIFICATE OF INCORPORATION IS ALSO AVAILABLE TO THE PUBLIC THROUGH THE SECRETARY OF STATE OF NEW YORK. ASCO'S CONFLICT OF INTEREST POLICY IS POSTED ON ASCO'S WEBSITE AND IS AVAILABLE TO THE PUBLIC FROM ASCO UPON REQUEST. FORM 990, PART VI, SECTION C, LINE 19 ASCO'S GOVERNING DOCUMENTS ARE AVAILABLE TO THE PUBLIC FROM ASCO UPON REQUEST. ASCO'S CERTIFICATE OF INCORPORATION IS ALSO AVAILABLE TO THE PUBLIC THROUGH THE SECRETARY OF STATE OF NEW YORK. ASCO'S CONFLICT OF INTEREST POLICY IS POSTED ON ASCO'S WEBSITE AND IS AVAILABLE TO THE PUBLIC FROM ASCO UPON REQUEST. FORM 990, PART IX, LINE 11G OTHER PROFESSIONAL SERVICES: PROGRAM SERVICE EXPENSES 18,279,375. MANAGEMENT AND GENERAL EXPENSES 1,517,935. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 19,797,310. ASCO LEASING LLC 2318 MILL RD SUITE 800 ALEXANDRIA VA 22314 273378225 RENTAL VA 0 0 ASCO CANCERLINQ LLC 2318 MILL RD SUITE 800 ALEXANDRIA VA 22314 472315885 QUALITY IMPV VA 14933493 1220870 ASCO CONQUER CANCER FOUNDATION OF ASCO 2318 MILL RD SUITE 800 ALEXANDRIA VA 22314 311667995 GRANTMAKING VA 501(C)(3) LINE 7 ASCO 1 ASCO ASSOCIATION 2318 MILL RD SUITE 800 ALEXANDRIA VA 22314 833561693 MEMBER SERVS VA 501(C)(6) ASCO 1 ASCO ASSOCIATION POLITICAL ACTION COMM 2318 MILL RD SUITE 800 ALEXANDRIA VA 22314 844213157 ADVOCACY VA 527 ASCO ASSOC 0 CANCERLINQ LABS LLC 2318 MILL ROAD SUITE 800 ALEXANDRIA VA 22314 881804716 DATABASE TECHNOLOGY VA N/A C 0 1 1 1 0 0 0 0 0 0 1 0 1 1 1 1 1 1 0 0 ASCO ASSOCIATION A 246581 FMV CONQUER CANCER FOUNDATION OF ASCO B 3514500 FMV CONQUER CANCER FOUNDATION OF ASCO C 9233468 FMV ASCO ASSOCIATION N 784200 FMV CONQUER CANCER FOUNDATION OF ASCO N 484420 FMV ASCO ASSOCIATION Q 897152 FMV CONQUER CANCER FOUNDATION OF ASCO Q 8327776 FMV